Sutro Biopharma (FRA:S090) Tariff Resilience Score: 6/10 (As of Jul. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:S090 Sutro Biopharma Inc FRA:S090
41 GF Score
Price €21.20
GF Value €10.31
! 4 Warning Signs
View Full Analysis

What is Sutro Biopharma Tariff Resilience Score?

Sutro Biopharma FRA:S090 -10.40% 41 Tariff Resilience Score is 6 as of Jul. 15, 2026. GuruFocus rates FRA:S090 with a GF Score™ of 41/100 and a GF Value™ of €10.31. The stock has 4 warning signs investors should review. Among 1,370 Biotechnology companies, Sutro Biopharma ranks better than 75.99% on this metric.

Sutro Biopharma has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Sutro Biopharma has Sutro Biopharma's exposure to tariffs is moderate, with potential impacts on imported raw materials for drug development. However, its focus on innovation and partnerships provides some resilience.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Sutro Biopharma might have Average Resilient.

Sutro Biopharma  (FRA:S090) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Sutro Biopharma Tariff Resilience Score Related Terms

FRA:S090 vs NGNE, OCGN, CBIO: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Sutro Biopharma's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sutro Biopharma Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sutro Biopharma's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Sutro Biopharma's Tariff Resilience Score falls into.


FRA:S090
41GF Score
Sutro Biopharma Inc FRA:S090
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
Sutro Biopharma (FRA:S090) has a Tariff Resilience Score of 6 as of Jul. 15, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Sutro Biopharma ranks #329 out of 1370 companies in the Biotechnology industry, placing it in the top 24%.
Is Sutro Biopharma's Tariff Resilience Score too high?
Sutro Biopharma's current Tariff Resilience Score is 6. The Biotechnology industry median Tariff Resilience Score is 4.00. Sutro Biopharma's value of 6 is 50% above this industry median. Based on the distribution chart, Sutro Biopharma ranks #329 out of 1370 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Sutro Biopharma has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Sutro Biopharma's Tariff Resilience Score compare to NGNE and OCGN?
According to the Biotechnology industry distribution chart, Sutro Biopharma ranks #329 out of 1370 companies for Tariff Resilience Score. This places Sutro Biopharma in the top 24% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Sutro Biopharma's value of 6 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,370 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sutro Biopharma's current Tariff Resilience Score of 6 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sutro Biopharma's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sutro Biopharma stock overvalued right now?
Sutro Biopharma (FRA:S090) has a current Tariff Resilience Score of 6. The stock's GF Value™ is €10.31, compared to a current price of €21.20 — trading 105.6% above its estimated fair value. The current Tariff Resilience Score is 6 and 50% above the Biotechnology industry median of 4.00. Sutro Biopharma's overall GF Score™ is 41/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Sutro Biopharma (FRA:S090), the current Tariff Resilience Score is 6 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sutro Biopharma (FRA:S090) Overvalued in 2026?

Based on GuruFocus' analysis, Sutro Biopharma stock appears to be overvalued. The current stock price of €21.20 is trading 105.6% above its estimated GF Value™ of €10.31.

Key valuation signals for FRA:S090:

  • Tariff Resilience Score: 6
  • GF Value™: €10.31 vs. price of €21.20 (105.6% above fair value)
  • GF Score™: 41/100 with 4 warning signs
  • Industry Position: 50% above the Biotechnology median (#329 of 1370)

No single metric tells the full story. See the FRA:S090 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sutro Biopharma Business Description

Other Exchanges STRO:USA
Address 111 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
41GF Score

Get the complete analysis for FRA:S090

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€21.20
Price
€10.31
GF Value